Key Safety Findings
Integrated safety analysis of 40 patients in the Ntrust program showed no reported cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), or graft-versus-host disease (GvHD). There were no deaths and no treatment discontinuations resulting from adverse events. Additionally, no cases of fludarabine-associated leukoencephalopathy were reported.
Technical Details and Patient Cohort
The analysis included patients with systemic sclerosis, myositis, lupus nephritis, rheumatoid arthritis, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The cohort consisted of patients with active or progressive disease; 75% (30 patients) had received four or more prior treatments, with a median disease duration of 4.7 years. Patients underwent outpatient lymphodepleting preconditioning using fludarabine and cyclophosphamide before receiving a three-dose cycle of NKX019.
- Dosing Distribution: 70% (28 patients) received 4 billion cells, 17.5% (7 patients) received 2 billion cells, and 12.5% (5 patients) received 1 billion cells.
- Adverse Events: Treatment-emergent adverse events occurred in 85% (34 patients). Grade 3 or higher events occurred in 35% (14 patients), primarily hematologic issues attributed to lymphodepletion.
- Infusion Reactions: 12.5% (5 patients) experienced infusion-related reactions associated with NKX019 (four grade 1, one grade 3), all of which resolved within 24-48 hours without the use of tocilizumab.
Background and Biological Context
NKX019 is an allogeneic, off-the-shelf, CD19-directed CAR NK cell therapy. According to Nkarta CEO Paul J. Hastings, CAR NK cells differ from CAR T cells because they are designed for targeted B-cell depletion with limited in vivo expansion and more predictable cellular exposure. This biological difference is intended to avoid the toxicities typically associated with autologous T cell-based modalities.
Significance and Outlook
The data, presented at ACR Convergence 2026 with a cutoff date of September 18, 2026, suggests that the safety profile of NKX019 remains consistent regardless of dose, as no increase in adverse events was observed at higher doses.
Source: https://finance.yahoo.com/healthcare/articles/nkarta-presents-initial-safety-data-120000700.html
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime



